Predictive Oncology Valuation
| POAI Stock | USD 1.11 0.01 0.91% |
Today, the company appears to be undervalued. Predictive Oncology holds a recent Real Value of $1.61 per share. The prevailing price of the company is $1.11. Our model determines the value of Predictive Oncology from analyzing the company fundamentals such as Return On Equity of -2.01, shares owned by insiders of 1.54 %, and Current Valuation of 7.47 M as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Predictive Oncology's valuation include:
Price Book 4.1436 | Enterprise Value | Enterprise Value Ebitda (0.51) | Price Sales 5.3433 | Enterprise Value Revenue 5.0301 |
Undervalued
Today
Please note that Predictive Oncology's price fluctuation is abnormally volatile at this time. Calculation of the real value of Predictive Oncology is based on 3 months time horizon. Increasing Predictive Oncology's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Predictive Oncology is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Predictive Stock. However, Predictive Oncology's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.11 | Real 1.61 | Target 3.0 | Hype 1.1 | Naive 1.26 |
The intrinsic value of Predictive Oncology's stock can be calculated using various methods such as discounted cash flow or dividend analysis. That value may differ from its market price, which is determined by factors such as investor sentiment, market trends, headlines, and other external factors that may influence Predictive Oncology's stock price.
Estimating the potential upside or downside of Predictive Oncology helps investors to forecast how Predictive stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Predictive Oncology more accurately as focusing exclusively on Predictive Oncology's fundamentals will not take into account other important factors: When choosing an evaluation method for Predictive Oncology, ensure it is appropriate for the firm given its current financial situation and market classification. If more than one evaluation category is relevant, we suggest using all methods to arrive at a better estimate.
Predictive Oncology Cash |
|
Predictive Valuation Trend
Predictive Oncology's real value analysis enables investors to forecast the earnings more efficiently. Using both Predictive Oncology's enterprise value as well as its market capitalization is the best way to gauging the value of the company and is usually enough for investors to make market timing decisions.
Predictive Oncology Total Value Analysis
Predictive Oncology is at this time forecasted to have valuation of 7.47 M with market capitalization of 7.93 M, debt of 2.86 M, and cash on hands of 25.39 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Predictive Oncology fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
7.47 M | 7.93 M | 2.86 M | 25.39 M |
Predictive Oncology Investor Information
The book value of the company was at this time reported as 0.3. The company recorded a loss per share of 2.96. Predictive Oncology last dividend was issued on the 29th of October 2019. The entity had 1:20 split on the 24th of April 2023. Based on the key measurements obtained from Predictive Oncology's financial statements, Predictive Oncology is not in a good financial situation at this time. It has a very high probability of going through financial hardship in April.Predictive Oncology Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Predictive Oncology has an asset utilization ratio of 12.35 percent. This signifies that the Company is making $0.12 for each dollar of assets. An increasing asset utilization means that Predictive Oncology is more efficient with each dollar of assets it utilizes for everyday operations.Predictive Oncology Ownership Allocation
Roughly 95.12 pct. of Predictive Oncology outstanding shares are held by general public with 1.54 % owned by insiders and only 3.34 (%) by third-party entities.Predictive Oncology Profitability Analysis
The company reported the previous year's revenue of 1.78 M. Net Loss for the year was (13.98 M) with profit before overhead, payroll, taxes, and interest of 681.38 K.About Predictive Oncology Valuation
An absolute valuation paradigm, as applied to Predictive Stock, attempts to find the value of Predictive Oncology based on its fundamental and basic technical indicators. By analyzing Predictive Oncology's financials, quarterly and monthly indicators, and their related drivers, such as dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of Predictive Oncology's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of Predictive Oncology. We calculate exposure to Predictive Oncology's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Predictive Oncology's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 1.3 M | 1.4 M | |
| Pretax Profit Margin | (7.07) | (7.42) | |
| Operating Profit Margin | (7.12) | (7.48) | |
| Net Loss | (7.07) | (7.42) | |
| Gross Profit Margin | 0.58 | 0.47 |
Predictive Oncology Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 4 M |
Predictive Oncology Current Valuation Indicators
Valuation refers to the process of determining the present value of Predictive Oncology and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Predictive we look at many different elements of the entity such as Predictive's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Predictive Oncology, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Predictive Oncology's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Predictive Oncology's worth.Complementary Tools for Predictive Stock analysis
When running Predictive Oncology's price analysis, check to measure Predictive Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Predictive Oncology is operating at the current time. Most of Predictive Oncology's value examination focuses on studying past and present price action to predict the probability of Predictive Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Predictive Oncology's price. Additionally, you may evaluate how the addition of Predictive Oncology to your portfolios can decrease your overall portfolio volatility.
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments |